Screener
Beam Therapeutics BEAM Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuances of stock under ESPP | 1,510 | 1,501 |
| Proceeds from exercise of stock options | 2,025 | 719 |
| Proceeds from the issuance of debt, net of fees paid to lender | 93,886 | — |
| Payments of debt issuance costs | (813) | — |
| Net cash provided by (used in) financing activities | 96,608 | 473,379 |
| Net change in cash, cash equivalents and restricted cash | (6,636) | 244,406 |
| Cash, cash equivalents and restricted cash—beginning of period | 301,620 | 290,111 |
| Cash, cash equivalents and restricted cash—end of period | $294,984 | $534,517 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's financing cash flow?
- Beam Therapeutics (BEAM) reported financing cash flow of $96.61M in Q1 2026.
- How has Beam Therapeutics's financing cash flow changed year-over-year?
- Beam Therapeutics's financing cash flow decreased by 79.6% year-over-year, from $473.38M to $96.61M.
- What is the long-term trend for Beam Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Beam Therapeutics's financing cash flow has grown at a -10.8% compound annual growth rate (CAGR), from $756.14M to $478.05M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Beam Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude